SG11202108792WA - Substituted bicyclic compounds as farnesoid x receptor modulators - Google Patents
Substituted bicyclic compounds as farnesoid x receptor modulatorsInfo
- Publication number
- SG11202108792WA SG11202108792WA SG11202108792WA SG11202108792WA SG11202108792WA SG 11202108792W A SG11202108792W A SG 11202108792WA SG 11202108792W A SG11202108792W A SG 11202108792WA SG 11202108792W A SG11202108792W A SG 11202108792WA SG 11202108792W A SG11202108792W A SG 11202108792WA
- Authority
- SG
- Singapore
- Prior art keywords
- farnesoid
- receptor modulators
- substituted bicyclic
- bicyclic compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806066P | 2019-02-15 | 2019-02-15 | |
| PCT/US2020/018203 WO2020168143A1 (en) | 2019-02-15 | 2020-02-14 | Substituted bicyclic compounds as farnesoid x receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108792WA true SG11202108792WA (en) | 2021-09-29 |
Family
ID=69811921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108792WA SG11202108792WA (en) | 2019-02-15 | 2020-02-14 | Substituted bicyclic compounds as farnesoid x receptor modulators |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11254663B2 (enExample) |
| EP (1) | EP3924336A1 (enExample) |
| JP (1) | JP7476216B2 (enExample) |
| KR (1) | KR102927636B1 (enExample) |
| CN (1) | CN113710656B (enExample) |
| AR (1) | AR118050A1 (enExample) |
| AU (1) | AU2020223316A1 (enExample) |
| BR (1) | BR112021015689A2 (enExample) |
| CA (1) | CA3129492A1 (enExample) |
| CL (1) | CL2021002093A1 (enExample) |
| CO (1) | CO2021010611A2 (enExample) |
| EA (1) | EA202192276A1 (enExample) |
| IL (1) | IL285246B2 (enExample) |
| MX (1) | MX2021009694A (enExample) |
| PE (1) | PE20211701A1 (enExample) |
| SG (1) | SG11202108792WA (enExample) |
| TW (1) | TWI808305B (enExample) |
| WO (1) | WO2020168143A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113677666A (zh) * | 2019-02-15 | 2021-11-19 | 百时美施贵宝公司 | 作为类法尼醇x受体调节剂的经取代的双环化合物 |
| WO2021144330A1 (en) | 2020-01-15 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| US20230165853A1 (en) | 2021-01-14 | 2023-06-01 | Enyo Pharma | Method for treating chronic kidney diseases |
| KR20230154806A (ko) | 2021-01-14 | 2023-11-09 | 엔요 파마 | Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과 |
| CN117320722A (zh) | 2021-04-28 | 2023-12-29 | 埃尼奥制药公司 | 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用 |
| KR20250004854A (ko) * | 2022-04-29 | 2025-01-08 | 장슈 야홍 메디텍 코퍼레이션 리미티드 | 피리미딘 화합물, 이의 제조 방법 및 이의 약학적 용도 |
| CN115057996B (zh) * | 2022-06-24 | 2023-06-02 | 河南工程学院 | 4CzIPN型多孔有机聚合物的制备方法及其应用 |
| WO2025012038A1 (en) * | 2023-07-13 | 2025-01-16 | Enyo Pharma | L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof |
| WO2025012422A1 (en) * | 2023-07-13 | 2025-01-16 | Enyo Pharma | L-arginine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993013101A1 (fr) | 1991-12-27 | 1993-07-08 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de pyridonecarboxylate, son utilisation pharmaceutique et compose spiro |
| AU4999897A (en) | 1996-10-25 | 1998-05-15 | Merck & Co., Inc. | Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists |
| EP1480957A1 (en) | 2002-03-01 | 2004-12-01 | Smithkline Beecham Corporation | Hppars activators |
| TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| US7189712B2 (en) | 2002-10-10 | 2007-03-13 | Smithkline Beecham Corporation | 1,3-Oxazole compounds for the treatment of cancer |
| AU2003290796A1 (en) | 2002-11-14 | 2004-06-15 | The Scripps Research Institute | Non-steroidal fxr agonists |
| WO2006006490A1 (ja) | 2004-07-08 | 2006-01-19 | Ono Pharmaceutical Co., Ltd. | スピロ化合物 |
| PT2402002T (pt) | 2005-04-08 | 2018-10-08 | Ptc Therapeutics Inc | Composições de 1,2,4-oxadiazole oralmente activo para terapia de supressão de mutações nonsense |
| JP5081161B2 (ja) | 2005-12-19 | 2012-11-21 | スミスクライン ビーチャム コーポレーション | ファルネソイドｘ受容体アゴニスト |
| US20120065196A1 (en) | 2006-07-21 | 2012-03-15 | Shuji Kitamura | Amide compounds |
| CL2007003035A1 (es) | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
| WO2008094556A2 (en) | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
| CA2690406A1 (en) | 2007-07-02 | 2009-01-08 | Glaxosmithkline Llc | Farnesoid x receptor agonists |
| WO2009009059A1 (en) | 2007-07-09 | 2009-01-15 | Biogen Idec Ma Inc. | Spiro compounds as antagonists of tgf-beta |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| AU2008317057B8 (en) | 2007-10-22 | 2014-02-13 | Merck Sharp & Dohme Corp. | Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119 |
| US20110230493A1 (en) | 2008-11-21 | 2011-09-22 | Pfizer Inc. | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors |
| JP2012532914A (ja) | 2009-07-15 | 2012-12-20 | メルク セローノ ソシエテ アノニム | テトラゾール誘導体 |
| US8440710B2 (en) | 2009-10-15 | 2013-05-14 | Hoffmann-La Roche Inc. | HSL inhibitors useful in the treatment of diabetes |
| WO2012087520A1 (en) | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| CN104364239B (zh) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
| JP6099753B2 (ja) | 2012-10-03 | 2017-03-22 | アドビナス セラピューティクス リミテッド | スピロ環化合物、その組成物及びその医薬応用 |
| EP2917203B1 (en) | 2012-11-02 | 2019-04-03 | Dana-Farber Cancer Institute, Inc. | Method for identifying myc inhibitors |
| US20140213538A1 (en) | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| WO2015005901A1 (en) | 2013-07-09 | 2015-01-15 | Bristol-Myers Squibb Company | Combinations of hepatitis c virus inhibitors |
| WO2015172747A1 (en) | 2014-05-16 | 2015-11-19 | Zhaoyin Wang | Spirocyclic molecules as mth1 inhibitors |
| US9956220B2 (en) | 2014-06-19 | 2018-05-01 | Bristol-Myers Squibb Company | Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors |
| WO2016039734A1 (en) | 2014-09-10 | 2016-03-17 | Halliburton Energy Services, Inc. | Perforating gun with integrated retaining system |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| US20170368038A1 (en) | 2014-12-18 | 2017-12-28 | Novartis Ag | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases |
| CN106146483A (zh) | 2015-04-23 | 2016-11-23 | 上海迪诺医药科技有限公司 | 杂环类法尼酯衍生物x受体调节剂 |
| WO2017049173A1 (en) * | 2015-09-16 | 2017-03-23 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| EP3350166A4 (en) * | 2015-09-16 | 2019-05-01 | Metacrine, Inc. | FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF |
| CN106946867B (zh) | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| CN107021958A (zh) | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| WO2017133521A1 (zh) | 2016-02-01 | 2017-08-10 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| MX384205B (es) | 2016-02-22 | 2025-03-14 | Novartis Ag | Metodos para usar agonistas de fxr. |
| SI3419624T1 (sl) | 2016-02-22 | 2021-05-31 | Novartis Ag | Postopki za uporabo agonistov FXR |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| AR108711A1 (es) | 2016-06-13 | 2018-09-19 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4) |
| CN108430998B (zh) | 2016-09-28 | 2021-07-09 | 四川科伦博泰生物医药股份有限公司 | 氮杂双环衍生物及其制备方法和用途 |
| CN106632294A (zh) | 2016-12-15 | 2017-05-10 | 宁波百纳西药业有限公司 | 一种螺环化合物及其药物用途 |
| LT3609888T (lt) | 2017-03-15 | 2025-11-10 | Farnezoidinio x receptoriaus agonistai ir jų panaudojimas | |
| WO2018170173A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| WO2018170167A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| WO2018170165A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| IL269068B (en) | 2017-03-15 | 2022-09-01 | Metacrine Inc | Paranoid x receptor agonists and uses thereof |
| CN113613649A (zh) | 2019-01-28 | 2021-11-05 | 弗拉特利发现实验室有限责任公司 | 用于治疗囊肿状纤维化的化合物及其治疗方法 |
| JP7602469B2 (ja) | 2019-02-15 | 2024-12-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン |
| KR20210129684A (ko) | 2019-02-15 | 2021-10-28 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서 유용한 치환된 아미드 화합물 |
| CN113677204B (zh) | 2019-02-15 | 2024-03-05 | 桑科能源股份有限公司 | 原卟啉ix衍生物改善植物健康的用途 |
-
2020
- 2020-02-11 AR ARP200100360A patent/AR118050A1/es not_active Application Discontinuation
- 2020-02-13 US US16/789,551 patent/US11254663B2/en active Active
- 2020-02-14 EA EA202192276A patent/EA202192276A1/ru unknown
- 2020-02-14 KR KR1020217029597A patent/KR102927636B1/ko active Active
- 2020-02-14 CN CN202080029369.9A patent/CN113710656B/zh active Active
- 2020-02-14 PE PE2021001326A patent/PE20211701A1/es unknown
- 2020-02-14 BR BR112021015689-5A patent/BR112021015689A2/pt unknown
- 2020-02-14 SG SG11202108792WA patent/SG11202108792WA/en unknown
- 2020-02-14 TW TW109104696A patent/TWI808305B/zh not_active IP Right Cessation
- 2020-02-14 EP EP20711418.2A patent/EP3924336A1/en active Pending
- 2020-02-14 MX MX2021009694A patent/MX2021009694A/es unknown
- 2020-02-14 CA CA3129492A patent/CA3129492A1/en active Pending
- 2020-02-14 JP JP2021547528A patent/JP7476216B2/ja active Active
- 2020-02-14 IL IL285246A patent/IL285246B2/en unknown
- 2020-02-14 WO PCT/US2020/018203 patent/WO2020168143A1/en not_active Ceased
- 2020-02-14 AU AU2020223316A patent/AU2020223316A1/en not_active Abandoned
-
2021
- 2021-08-10 CL CL2021002093A patent/CL2021002093A1/es unknown
- 2021-08-12 CO CONC2021/0010611A patent/CO2021010611A2/es unknown
- 2021-12-07 US US17/544,490 patent/US11713312B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021002093A1 (es) | 2022-02-18 |
| MX2021009694A (es) | 2021-09-10 |
| EA202192276A1 (ru) | 2021-11-26 |
| BR112021015689A2 (pt) | 2021-10-26 |
| US11254663B2 (en) | 2022-02-22 |
| AR118050A1 (es) | 2021-09-15 |
| US20210261535A1 (en) | 2021-08-26 |
| IL285246A (en) | 2021-09-30 |
| KR20210127220A (ko) | 2021-10-21 |
| TW202045498A (zh) | 2020-12-16 |
| WO2020168143A1 (en) | 2020-08-20 |
| CO2021010611A2 (es) | 2021-08-30 |
| IL285246B1 (en) | 2024-05-01 |
| TWI808305B (zh) | 2023-07-11 |
| US11713312B2 (en) | 2023-08-01 |
| EP3924336A1 (en) | 2021-12-22 |
| CA3129492A1 (en) | 2020-08-20 |
| AU2020223316A1 (en) | 2021-10-07 |
| PE20211701A1 (es) | 2021-09-01 |
| JP2022519770A (ja) | 2022-03-24 |
| JP7476216B2 (ja) | 2024-04-30 |
| KR102927636B1 (ko) | 2026-02-12 |
| CN113710656B (zh) | 2026-04-17 |
| US20220135550A1 (en) | 2022-05-05 |
| CN113710656A (zh) | 2021-11-26 |
| IL285246B2 (en) | 2024-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274321A (en) | Bridged bicyclic compounds as farnesoid X receptor modulators | |
| SG11202108792WA (en) | Substituted bicyclic compounds as farnesoid x receptor modulators | |
| IL287222A (en) | bicyclic compounds | |
| IL292156A (en) | Transduced azacils as trmp8 modulators | |
| ZA202207722B (en) | Substituted tricyclic compounds | |
| IL282984A (en) | bicyclic compounds | |
| ZA202206253B (en) | Substituted tricyclic compounds | |
| SG11202108796YA (en) | Substituted bicyclic compounds as farnesoid x receptor modulators | |
| IL274322A (en) | Spirocyclic compounds as paranoid X receptor modulators | |
| GB201911187D0 (en) | Receptor | |
| ZA201802901B (en) | Farnesoid x receptor modulators | |
| IL285630A (en) | Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor | |
| IL274320A (en) | Spirocyclic alkene compounds as paranoid X receptor modulators | |
| IL283067A (en) | Improved synthetic methods for the preparation of condensed heterocyclic compounds as orexin receptor modulators | |
| SG11202101499UA (en) | Heterocyclic compounds as ahr modulators | |
| SG11202108794RA (en) | Substituted amide compounds useful as farnesoid x receptor modulators | |
| IL285570A (en) | Bicyclic compounds substituted as farnesoid receptor modulators | |
| IL307453A (en) | Opioid receptor modulators | |
| IL289575A (en) | nmda receptor modulators | |
| EP3765009A4 (en) | BICYCLIC ROR-GAMMA MODULATORS | |
| SG11202108798XA (en) | Substituted amide compounds useful as farnesoid x receptor modulators | |
| GB201805675D0 (en) | Compounds For Use As Apelin Receptor Antagonists | |
| HK40065843A (en) | Substituted bicyclic compounds as farnesoid x receptor modulators | |
| SMT202600012T1 (it) | Composti antagonisti del recettore della prostaglandina ep4 | |
| HK40034433A (en) | Bridged bicyclic compounds as farnesoid x receptor modulators |